TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30156758
Drug: ABBV-257 (single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABBV-257 (single-dose study)
Study: 30156758
Drug: ABBV-257 (multiple-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABBV-257 (multiple-dose study)
Study: 30351407
Drug: Renin-angiotensin system
Normalized name: Renin-angiotensin system inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renin-angiotensin system inhibitors (RASi)
Study: 30351407
Drug: Non-renin-angiotensin system
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-renin-angiotensin system inhibitors (non-RASi)
Study: 27456597
Drug: Microcrystalline cellulose
Normalized name: Microcrystalline Cellulose
DrugBank: Microcrystalline cellulose (DB14158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microcrystalline cellulose nasal spray
Study: 17388220
Drug: Fexofenadine hydrochloride
Normalized name: Fexofenadine Hydrochloride
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine hydrochloride 180 mg once daily
Study: 10795758
Drug: Erythromycin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (200 mg intravenous) during normoglycemia (5-8.9 mmol/liter glucose)
Study: 10795758
Drug: Erythromycin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (200 mg intravenous) during hyperglycemia (16-19 mmol/liter glucose)
Study: 1485474
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg dipyridamole per day
Study: 18812486
Drug: Oral DHEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral DHEA 50 mg/d for 12 months
Study: 16480006
Drug: Biological valve
Normalized name: VALVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological valve (Medtronic Mosaic or Medtronic Freestyle)
Study: 8393272
Drug: Chemohormonal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemohormonal therapy (group A) including 60 mg/m2 of cisplatin (CDDP), 13 mg/m2 of Adriamycin (ADM), 150 mg of 5‐fluorouracil (5‐FU), Tamoxifen (TAM) 25 mg/m2 daily, and medroxyprogesterone acetate (MPA) 400 mg/m2 daily, administered orally and alternated every 4 weeks
Study: 8393272
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (group B) receiving the same anticancer drugs without hormonal agents
Study: 29161531
Drug: Inhaled levodopa
Normalized name: levodopa Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled levodopa (CVT-301) 25 mg
Study: 29161531
Drug: Inhaled levodopa
Normalized name: levodopa Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled levodopa (CVT-301) 50 mg
Study: 29161531
Drug: Inhaled levodopa
Normalized name: levodopa Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled levodopa (CVT-301) 35 mg (weeks 1-2)
Study: 29161531
Drug: Inhaled levodopa
Normalized name: levodopa Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled levodopa (CVT-301) 50 mg (weeks 3-4)
Study: 28009467
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioral therapy (iCBT) for 10 weeks, including six online therapy lessons with content summaries and homework assignments
Study: 25627338
Drug: Golimumab 50
Normalized name: GOLIMUMAB 50MG/0.5ML INJ SYRINGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golimumab 50 mg or 100 mg (based on escape status)
Study: 22981787
Drug: Cat-PAD (6-nmol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cat-PAD (6-nmol dose, 4 administrations, 4 weeks apart)
Study: 22981787
Drug: Cat-PAD (3-nmol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cat-PAD (3-nmol dose, 8 administrations, 2 weeks apart)
Study: 17938887
Drug: Heparinized solution
Normalized name: heparin Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparinized solution (1 IU/ml)
Study: 17938887
Drug: Heparinized solution
Normalized name: heparin Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparinized solution
Study: 17053959
Drug: Volume expansion
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume expansion with saline and intravenous infusion of octreotide
Study: 7538658
Drug: Lenograstim (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenograstim (twice daily on alternate days)
Study: 7538658
Drug: Lenograstim therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenograstim therapy
Study: 3262980
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of 1 ml of lignocaine (10 mg) to 19 ml of propofol
Study: 3262980
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline added to 19 ml of propofol
Study: 21424272
Drug: Treatment supporter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment supporter intervention (TS arm)
Study: 9682999
Drug: Amisulpride (ASP)
DrugBank: Amisulpride (DB06288)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amisulpride (ASP) 1000 mg/day (mean daily dose: 956 mg)
Study: 9682999
Drug: Flupentixol (FPX)
DrugBank: Flupentixol (DB00875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupentixol (FPX) 25 mg/day (mean daily dose: 22.6 mg)
Study: 8562296
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors (captopril or enalapril)
Study: 8562296
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (non-ACE inhibitors)
Study: 120757
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate (maximum tolerated doses)
Study: 28385352
Drug: MLE4901 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLE4901 (40 mg, orally, twice daily)
Study: 28385352
Drug: Placebo (orally,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (orally, twice daily)
Study: 24083696
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Ringer's solution)
Study: 17916806
Drug: tiotropium 18
Normalized name: TIOTROPIUM 18MCG CAP,INHL,6
Approvals — FDA: no, EMA: no, PMDA: no
Description: tiotropium 18 microg once daily
Study: 7163513
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no oxytocin infusion)
Study: 27114421
Drug: Sequential Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential Therapy (ST) for 10 days
Study: 27114421
Drug: Triple Therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple Therapy (TT) for 7 days
Study: 25270152
Drug: Rituximab as
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab as induction therapy after renal transplantation
Study: 20200306
Drug: Age and
Normalized name: wound drainage and fistula management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age and insulin modality (pump vs multiple daily injections)
Study: 16808313
Drug: Pentaerythritol compositum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentaerythritol compositum (20 mg of pentaerythritol tetranitrate and 0.5 mg of nitroglycerine)
Study: 16808313
Drug: Nitroglycerine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerine (0.5 mg)
Study: 12011664
Drug: ASA 75
Normalized name: ASA 75 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA 75 mg daily
Study: 2407227
Drug: Intra-arterial infusion
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial infusion with doxorubicin hydrochloride (Adriamycin) 30 mg every 24 hours for 3 days, followed by irradiation (30 or 35 Gy in 10 fractions or 46 Gy in 23 to 25 fractions)
Study: 27966318
Drug: Levofloxacin administration
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin administration after EMR (Group B)
Study: 27966318
Drug: Ceftazidime administration
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime administration after EMR (Group C)
Study: 27966318
Drug: No antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotics treatment after EMR (Group A)
Study: 25730927
Drug: Low-frequency magnetic
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-frequency magnetic therapy
Study: 15721091
Drug: Bucindolol therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bucindolol therapy
Study: 10535346
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg mifepristone orally followed by gemeprost 1 mg vaginally 24 hours later
Study: 10535346
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg mifepristone orally followed by gemeprost 1 mg vaginally 48 hours later
Study: 1654983
Drug: As required
Normalized name: rabies vaccine, for intramuscular injection RETIRED CODE
Approvals — FDA: no, EMA: no, PMDA: no
Description: As required (AR) chemotherapy
Study: 1654983
Drug: Planned chemotherapy
Normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Planned chemotherapy
Study: 1654983
Drug: As required
Normalized name: rabies vaccine, for intramuscular injection RETIRED CODE
Approvals — FDA: no, EMA: no, PMDA: no
Description: As required (AR) chemotherapy with treatment-free interval (TFI) greater than 8 weeks
Study: 1654983
Drug: As required
Normalized name: rabies vaccine, for intramuscular injection RETIRED CODE
Approvals — FDA: no, EMA: no, PMDA: no
Description: As required (AR) chemotherapy with treatment-free interval (TFI) less than 4 weeks
Study: 26598747
Drug: Alectinib 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alectinib 600 mg orally twice daily
Study: 24339179
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol (CZP) 400 mg at weeks 0, 2, and 4, followed by either CZP 200 mg every 2 weeks or CZP 400 mg every 4 weeks
Study: 24339179
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol (CZP) 200 mg every 2 weeks or CZP 400 mg every 4 weeks
Study: 22903484
Drug: No bowel
Approvals — FDA: no, EMA: no, PMDA: no
Description: No bowel preparation and allowed to eat and drink before examination (group 2)
Study: 15260469
Drug: Inspiratory flow
Normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory flow at 20 L/min
Study: 15260469
Drug: Inspiratory flow
Normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory flow at 60 L/min
Study: 9688295
Drug: Cisplatin (DDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (DDP) in combination with ifosfamide (IFO) and vinorelbine (VNB)
Study: 9688295
Drug: Ifosfamide (IFO)
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ifosfamide (IFO) and vinorelbine (VNB) plus G-CSF
Study: 8075441
Drug: 0.3% podophyllotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% podophyllotoxin cream
Study: 782964
Drug: H3N2 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: H3N2 vaccine
Study: 782964
Drug: HEqN2 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEqN2 vaccine
Study: 782964
Drug: Placebo vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo vaccine (vaccine diluent)
Study: 31612398
Drug: USG II/IHN
Approvals — FDA: no, EMA: no, PMDA: no
Description: USG II/IHN plus GFN block (Group G)
Study: 19228800
Drug: Home telemonitoring
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home telemonitoring (HT) - three strategies: (i) monthly telephone contact; (ii) monthly telephone contact plus weekly transmission of vital signs; (iii) strategy 2 plus monthly 24 h recording of cardiorespiratory activity
Study: 14645935
Drug: Combined patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined patch groups (active + placebo)
Study: 10537958
Drug: Continuous intrathecal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intrathecal baclofen infusion
Study: 31059495
Drug: Biannual mass
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biannual mass drug administration (MDA) with praziquantel alone
Study: 25035603
Drug: Yoga group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga group (with standard medical treatment and yogic intervention)
Study: 25035603
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard medical treatment without yogic intervention)
Study: 22181063
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (iGlar) with regular insulin (iReg)
Study: 12764986
Drug: Live Lactobacillus
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live Lactobacillus plantarum 299 (10^9 live bacteria) with oat fibre substrate, administered twice daily for 7 days.
Study: 12764986
Drug: Heat-killed Lactobacillus
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-killed Lactobacillus plantarum 299, administered twice daily for 7 days.
Study: 12764986
Drug: Live Lactobacillus
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live Lactobacillus plantarum 299 (treatment group)
Study: 10021717
Drug: Prophylaxis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylaxis with 200 mg/kg of porcine surfactant
Study: 8418402
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment and selective ERCP with or without endoscopic papillotomy
Study: 31315446
Drug: Monthly telemedical
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly telemedical consultations in addition to regular care
Study: 29573247
Drug: Quadrivalent Influenza
Normalized name: influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injection [Fluzone Quadrivalent 2021-2022]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent Influenza Vaccine (GC3110A)
Study: 29573247
Drug: Trivalent Influenza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent Influenza Vaccine (Control)
Study: 21596578
Drug: Bupivacaine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (1.5 mg kg(‐1) via paravertebral subpleural catheter for 3 days)
Study: 21596578
Drug: Morphine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.2 mg kg(‐1) via paravertebral subpleural catheter for 3 days)
Study: 21596578
Drug: Control (tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (tramadol 100 mg plus metamizol 1000 mg intravenously every 4 h for 3 days)
Study: 20438942
Drug: Chemotherapy +/-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy +/- radiation therapy or surgery alone (historical controls)
Study: 30878487
Drug: rAAV.sFLT-1 gene
Approvals — FDA: no, EMA: no, PMDA: no
Description: rAAV.sFLT-1 gene therapy (GT)
Study: 27567022
Drug: Radial extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial extracorporeal shock wave treatment (rESWT) - two sessions, 2,000 shock waves per session, energy flux density of 0.16 mJ/mm2
Study: 27567022
Drug: Radial extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial extracorporeal shock wave treatment (rESWT)
Study: 26639151
Drug: Leaf concentrate
Normalized name: Belladonna Leaf
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leaf concentrate powder (LCP) 10 g daily
Study: 26639151
Drug: Skimmed milk
Normalized name: Calcium fortified skimmed milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skimmed milk powder (SMP) 15 g daily
Study: 18952469
Drug: Face-to-face treatments
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face treatments
Study: 15327047
Drug: 4-aminopyridine (4-AP)
Normalized name: 4-AP
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-aminopyridine (4-AP) 24 mg/day
Study: 15327047
Drug: fluoxetine (FLX)
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: fluoxetine (FLX) 20 mg/day
Study: 11346221
Drug: Meloxicam 7.5
Normalized name: meloxicam 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam 7.5 mg daily for 4 weeks
Study: 11346221
Drug: Piroxicam 20
Normalized name: piroxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 20 mg daily for 4 weeks
Study: 8431908
Drug: Concurrent chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemotherapy with extended field radiation
Study: 3631918
Drug: Scopolamine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (0.25 mg)
Study: 22468766
Drug: Fructose +
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fructose + maltodextrin solution
Study: 22468766
Drug: Fructose +
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fructose + maltodextrin solution (adjusted for gastrointestinal discomfort)
Study: 16248240
Drug: Diane-35 in
Normalized name: Dianeal PD-2/2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diane-35 in the Western medicine group (WMG)
Study: 16248240
Drug: Conventional controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional controlled medicine plus modified Yougui Pill in the integrative medicine group (IMG)
Study: 9607357
Drug: Adriamycine, vincristine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adriamycine, vincristine (AV) alternated with CMF, then radiotherapy, followed by four cycles of chemotherapy (AV/CMF); and tamoxifen during the entire treatment period (arm III)
Study: 7617803
Drug: Nicotine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (20 micrograms/kg) administered 30 min before challenge
Study: 7617803
Drug: Nicotine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (20 micrograms/kg) administered 60 min before challenge
Study: 7617803
Drug: Nicotine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (20 micrograms/kg) administered 120 min before challenge
Study: 7617803
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered 30 min before challenge
Study: 65196
Drug: Candicidin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candicidin (300 mg daily dose, 6 capsules per day)
Study: 23828184
Drug: Combined massage-exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined massage-exercise therapy
Study: 21216512
Drug: Topical polyantibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical polyantibiotic ointment application at CVC exit sites (1 time/week)
Study: 21216512
Drug: Topical polyantibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical polyantibiotic ointment application at CVC exit sites
Study: 18989889
Drug: Paclitaxel at
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel at 250 mg/m2
Study: 18989889
Drug: Paclitaxel at
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel at 325 mg/m2
Study: 18989889
Drug: Paclitaxel at
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel at 425 mg/m2
Study: 18989889
Drug: Paclitaxel at
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel at 550 mg/m2
Study: 18989889
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of paclitaxel and ifosfamide
Study: 15282382
Drug: Asthma medication
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Asthma medication usage
Study: 11347287
Drug: Chlorella supplementation
Normalized name: Chlorella emersonii extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorella supplementation (10 g in tablet form and 100 mL liquid extract daily for 2 or 3 months)
Study: 3693583
Drug: Long-acting propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting propranolol 160 mg/d
Study: 3693583
Drug: Conventional propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional propranolol 40 mg qid
Study: 28377360
Drug: Shangbai ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shangbai ointment treatment
Study: 24092872
Drug: Dexamethasone (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.6 mg/kg, 1 dose)
Study: 17339866
Drug: Short-acting inhaler
Normalized name: Sinex Long-Acting Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting inhaler beta2 mimetic as required + 800 mug inhaler budesonide + leukotriene receptor antagonist
Study: 2658142
Drug: Mifepristone 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 400 mg/d
Study: 1103724
Drug: Variable Dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Variable Dosage Regimen (VDR)
Study: 22436099
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of nifedipine with 480 mg of curcuminoid (6 tablets of turmeric extract)
Study: 22436099
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of nifedipine (control)
Study: 9013080
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules (control group)
Study: 1521049
Drug: Cigarette yield,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigarette yield, consumption, self-reported inhalation, and puffing characteristics under standardized smoking conditions (30 puffs through a holder)
Study: 1521049
Drug: Cigarette yield,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigarette yield, consumption, self-reported inhalation, and puffing characteristics under natural smoking conditions